VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) specialized in Lentiviral vectors. VIVE is focused on the manufacture of Research, Preclinical toxicology and GMP-grade lentiviral vectors. Sealed as Excellence Centre by European Union, VIVEbiotech is currently working with Companies based both in Europe and USA being our main interest adapting to Customer requirements considering also planning and timelines related issues. Importanly, VIVEbiotech is also developing its Lentiviral vector related technology, LENTISOMA. LENTISOMA´s technology is a non-Integrative replicative episomal lentiviral vector .
Location: Spain, Autonomous Community of the Basque Country, San Sebastián
Employees: 51-200
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Stellum Ca... | stellumcap... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 08.06.2021 | El CDTI destina en mayo más de €2,2M a cinco nuevas coinvers... | 08/06/2021 Nota de prensa EL CDTI DESTINA EN MAYO MÁS DE €2,2 MILLONES A CINCO NUEVAS COINVERSIONE... | webcapital... |
| 04.06.2021 | VIVEbiotech, participada por Inveready y EASO Ventures, inau... | 04/06/2020 Nota de prensa VIVEBIOTECH, PARTICIPADA POR INVEREADY Y EASO VENTURES, INAUGURA SU NUEV... | webcapital... |
| 09.07.2020 | El CDTI invierte junto a Inveready Biotech III y EASO Ventur... | 08/07/2020 Nota de prensa EL CDTI INVIERTE JUNTO A INVEREADY BIOTECH III Y EASO VENTURES EN VIVEBI... | webcapital... |
| 09.09.2019 | Vivebiotech cierra una ronda de €3,5M liderada por Inveready... | 09/09/2019 Nota de prensa VIVEBIOTECH CIERRA UNA RONDA DE €3,5 MILLONES LIDERADA POR INVEREADY Y E... | webcapital... |